First human test of new drug for rare blood disorder

NCT ID NCT04269551

Completed Disease control Sponsor: Bioverativ, a Sanofi company Source: ClinicalTrials.gov ↗

Summary

This early-stage study tested the safety and effects of a single dose of an experimental drug called BIVV020 in 12 adults with cold agglutinin disease, a rare autoimmune condition where the immune system attacks red blood cells. The main goal was to see if the drug was safe and tolerable, and to measure how it affected the body's immune system and blood markers. Researchers also tracked how the drug moved through and was processed by the body.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Show contact details

Locations

Investigational Site Number :2760001

Essen, 45147, Germany
Investigational Site Number :3800001

Milan, Milano, 20122, Italy
Investigational Site Number :5280001

Amsterdam, 1105AZ, Netherlands
Investigational Site Number :5780001

Bergen, 5021, Norway
Investigational Site Number :8260001

London, London, City of, NW1 2PJ, United Kingdom
Investigational Site Number :8400002

Fayetteville, Georgia, 30214, United States
Investigational Site Number :8400004

Seattle, Washington, 98108, United States
Investigational Site Number :8400006

The Bronx, New York, 10467, United States
Investigational Site Number :8400008

Pittsburgh, Pennsylvania, 15232, United States
Investigational Site Number :8400009

St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

AUTOIMMUNE HAEMOLYTIC ANAEMIA